CompletedNot Applicable

6-minute Stepper Test and Pulmonary Rehabilitation in Patients With Chronicle Obstructive Pulmonary Disease

France105 participantsStarted 2016-07

Plain-language summary

The purpose of this study is to determine, if it exists, a relation between plateau heart rate from the last 3 minutes of the 6-minute stepper test and heart rate from first ventilatory threshold from cardiopulmonary exercise testing in order to individualise pulmonary rehabilitation in patients with mild to moderate chronicle obstructive pulmonary disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 ans ; * Chronicle obstructive pulmonary disease stage I/II (FEV1 ≥ 50%) ; * Chronicle obstructive pulmonary disease stage III/IV (FEV1 \< 50%) from may 2019 (ethical approvement granted) * Weight ≤ 90kg ; * Eligible for pulmonary rehabilitation. Exclusion Criteria: * Pregnant woman or likely to be ; * Patient under guardianship ; * Contraindication to cardiopulmonary exercise testing ; * Patient medically treated with heart rate modulator (excluding oral B2-agonist) ; * Patient treated with pacemaker or defibrillator ; * History of lower limb impairment (i.e. peripheral artery disease, orthopedic disorder etc.).

What they're measuring

Relation between plateau heart rate (bpm) from the first and last 3 minutes of the 6-minute stepper test and heart rate (bpm) from first ventilatory threshold from cardiopulmonary exercise testing.

Timeframe: Heart rate (bpm) will be assessed during cardiopulmonary exercise testing with electrocardiogram. During the 2 6-minute stepper test, heart will be assessed with oximeter. All theses tests wil be carried out in a total time frame of 3 month maximum.

Trial details

NCT IDNCT02842463

SponsorADIR Association

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Chronic Obstructive Pulmonary Disease trials